Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Objective To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy. M...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2017-02, Vol.69 (2), p.277-290
Hauptverfasser:	Fleischmann, Roy, van Adelsberg, Janet, Lin, Yong, Castelar‐Pinheiro, Geraldo da Rocha, Brzezicki, Jan, Hrycaj, Pawel, Graham, Neil M. H., van Hoogstraten, Hubert, Bauer, Deborah, Burmester, Gerd R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormalities Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arthritis Arthritis, Rheumatoid - drug therapy Double-Blind Method Drugs Female Gangrene Humans Infections Interleukins Intolerance Male Middle Aged Monoclonal antibodies Necrosis Neutrophils Patients Pharmaceutical industry Prescription drugs Rheumatoid Arthritis Safety Severity of Illness Index Signs and symptoms Transaminase Tumor necrosis factor Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!